IDT Australia : 2021 AGM Presentation

ersonal use only

IDT AUSTRALIA LIMITED

2021 ANNUAL GENERAL MEETING

16 November 2021

Key Operational Highlights

(1 July 2020 to present)

ersonal use only

Restored IDT to Profitability

• FY`21 results reported the Company's first operating profit since 2009
• 209.6% year-on-year increase in net profit after tax, from a loss of $1.9m in FY`20 to a profit of $2.1m in FY`21*

Sterile Manufacturing Licence Secured From The Therapeutic Goods Administration

• Finalised and successfully executed the Letter Agreement with the Australian Government, Department of Health
• IDT's cGMP sterile manufacturing facility brought into a state of readiness
• Sterile manufacturing licence secured from Therapeutic Goods Administration

Delivering On IDT's Sovereign Manufacturing Initiatives

• IDT has engaged with Monash University and mRNA Victoria to manufacture the Monash Institute of Pharmaceutical Sciences (MIPS) mRNA COVID-19 receptor binding domain vaccine drug product. Australia's first locally developed mRNA COVID-19 vaccine candidate
• IDT leveraging its existing TGA and FDA accredited pharmaceutical manufacturing facilities and capabilities to assist with the supply chain challenges brought about by the COVID-19 pandemic
• The Company's submissions to the Australian Government's Approach To Market and Modern Manufacturing Initiative (Collaboration Stream) funding opportunities remain live

Continuing To Execute On The Company's Medicinal Cannabis Manufacturing Plan

• • Finalised process development of cannabis resin products
  • Expanding stability data for flower-in-bottle and oil-in-bottle products
  • Advancing a pipeline of new product development opportunities
• Including one-time adjustments (includes $0.9 million of JobKeeper receipts)

FY`21 Year In Review*

	COVID-19 Treatment and
Vaccine Manufacture - TGA and		Advance IDT's Sovereign
FDA accredited site at the ready		Manufacturing Initiative
only		Pushing Towards A Return To	Continue To Execute IDT's
	Operational Profitability	Medicinal Cannabis
		Manufacturing Plan
	Finalise Development of
Proprietary Medicinal Cannabis		Proprietary Medicinal Cannabis
use	Products		Product Launches
ersonal
	Engage With Government and	Commence Domestic
	Industry to Map and Better	Manufacture of Essential
	Understand Australia's	Medicines
	Pharmaceutical Supply Chain
* Year ahead slide presented at IDT's 2020 AGM

	FY21 Financial Highlights
	First Operating Profit since 2009
only
	Year-on-year Revenue growth of 19.5% to $16.9
	million (which includes $0.9 million of JobKeeper
	receipts)
 Positive EBITDA achieved for full year 2021 which
	represents a year-on-year improvement of
	244.9%*
use Year-on-year increase in earnings per share of
	212.5%
ersonal
	Strong cash balance of $6.9 million

Year ended 30 June ($m)	2021	2020	Variance
Results from operations including one time adjustments*
Revenue	16,927	14,169	2,758		19.5%
EBITDA	2,718	788	1,930		244.9%
NPAT	2,103	(1,919)	4,022		209.6%
Basic earnings per share	0.9¢	(0.8¢)	1.7¢		212.5%

only use



ersonal

Sterile Manufacturing:

Sterile Readiness Agreement Finalised Site Licence Secured

Sterile Facility Ready To Accept Contract Development and Manufacturing Content

Sterile Readiness Letter Agreement finalised with the Australian Government Department of Health

IDT's flagship sterile manufacturing facility in Boronia brought into a state of sterile readiness so that IDT can use the facility to potentially provide assistance to the Government in connection with the Government's rollout of COVID-19 vaccines in Australia

Sterile Manufacturing Licence (the Company's first ever sterile licence) secured from the Therapeutic Goods Administration

IDT's sterile manufacturing facility is now licenced and can be deployed to support a range of sterile contract product development and manufacturing opportunities:

• For the Australian Government, during the Letter Agreement exclusivity period; and
• For third parties following the cessation of the Letter Agreement exclusivity period